Helmholtz Gemeinschaft


Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice

Item Type:Article
Title:Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice
Creators Name:Dowling, C.M. and Claffey, J. and Cuffe, S. and Fichtner, I. and Pampillon, C. and Sweeney, N.J. and Strohfeldt, K. and Watson, R.W. and Tacke, M.
Abstract:Chemotherapeutic options for androgen-independent prostate cancer are extremely limited with minimum survival advantage. The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl) cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against the human prostate cancer androgen-independent cell, PC-3, which demonstrated an IC50 value of 56 x 10(-6) mol/L compared to 5.6 x 10(-6) mol/L for cisplatin. Then Titanocene Y was given at the maximum tolerable dose of 40 mg/kg/d on five consecutive days to one cohort of eight PC3 tumor-bearing male NMRI: nu/nu mice, while a second cohort was treated similarly with 3 mg/kg/d of cisplatin. Both of these mouse cohorts showed a statistically significant tumor growth reduction with respect to the third solvent-treated control group, which led to T/C values of 42% for cisplatin and 52% for Titanocene Y at the end of the experiment. This encouraging activity of Titanocene Y against prostate tumors in vivo, which is almost comparable with respect to cisplatin hopefully leads to further development of Titanocene Y in the future.
Keywords:Anti-Cancer Drug, Cisplatin, Titanocene, Prostate Cancer, PC-3, Xenograft, Animals, Mice
Source:Letters in Drug Design & Discovery
Publisher:Bentham (U.K.)
Page Range:141-144
Date:March 2008
Official Publication:http://www.ingentaconnect.com/content/ben/lddd/2008/00000005/00000002/012aj
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library